TORONTO, Oct. 26, 2015 /CNW/ - Biosign Technologies Inc. (TSXV: BIO) ("Biosign" or the "Company") announces that it has granted incentive stock options ("Options") to directors, management and consultants for the purchase of a total of 1,105,000 common shares of the Company at an exercise price of $0.10 per share effective October 23, 2015.

The Options have a term of five years and are governed by the Company's Stock Option Plan pursuant to which Options may be granted up to a maximum of 10% of the issued and outstanding common shares of the Company from time to time and subject to any approval that may be required by the TSX Venture Exchange. All shares issuable pursuant to the exercise of Options are subject to a four-month hold period commencing from the date the Options are granted.

About Biosign Technologies Inc. (TSXV: BIO) Biosign is a developer of world class healthcare software solutions targeted at the Home Care markets with operations in Canada and Germany.

Forward-Looking Statements

This release contains forward-looking statements. Forward-looking statements, without limitation, may contain the words believes, expects, anticipates, estimates, intends, plans, or similar expressions. Forward-looking statements are not guarantees of future performance. They involve risks, uncertainties and assumptions and Biosign's actual results could differ materially from those anticipated. Forward looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. In the context of any forward-looking information please refer to risk factors detailed in, as well as other information contained in the company's filings with Canadian securities regulators (www.sedar.com).

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE Biosign Technologies Inc.